Beam Therapeutics vs Karius

Side-by-side comparison of AI visibility scores, market position, and capabilities

Karius leads in AI visibility (73 vs 53)
Beam Therapeutics logo

Beam Therapeutics

GrowthBiotechnology

Base Editing Gene Therapy

Beam Therapeutics develops precision genetic medicines using base editing technology that makes single-letter DNA changes without cutting the double helix.

AI VisibilityBeta
Overall Score
C53
Category Rank
#58 of 198
AI Consensus
76%
Trend
stable
Per Platform
ChatGPT
58
Perplexity
52
Gemini
48

About

Beam Therapeutics is a genetic medicines company founded in 2017 by base editing pioneers David Liu, J. Keith Joung, and Feng Zhang, having raised over $600M and gone public on Nasdaq. The company is built around base editing, a technology that makes precise single nucleotide changes in DNA without creating double-strand breaks, reducing the risk of unintended insertions or deletions compared to traditional CRISPR. Beam is developing a portfolio of base editing medicines targeting blood disorders, liver diseases, and immuno-oncology, including sickle cell disease, beta-thalassemia, and various cancers. The company also employs prime editing, a newer and even more precise gene editing modality for more complex genetic changes. Beam's pipeline includes both in vivo therapies delivered directly into the body and ex vivo cell therapy approaches where patient cells are edited outside the body and reinfused. As a clinical-stage company, Beam has programs in IND-enabling and Phase 1 trials and represents one of the most advanced next-generation gene editing platforms in development.

Full profile
Karius logo

Karius

LeaderLife Sciences & BioTech

Genomic Infectious Disease Diagnostics

Karius raised $409M total including a $100M Series C in May 2024; its genomic blood test detects 1,000+ pathogens at 400+ U.S. hospitals; launched Karius Focus BAL for pneumonia in April 2025.

AI VisibilityBeta
Overall Score
B73
Category Rank
#12 of 198
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
69
Perplexity
70
Gemini
70

About

Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens (bacteria, fungi, viruses, parasites) in seriously ill patients. The test is used when conventional cultures and targeted diagnostics fail, providing clinicians at transplant centers, children''s hospitals, and ICUs with a comprehensive pathogen report within 24 hours.

Full profile

AI Visibility Head-to-Head

53
Overall Score
73
#58
Category Rank
#12
76
AI Consensus
78
stable
Trend
stable
58
ChatGPT
69
52
Perplexity
70
48
Gemini
70
49
Claude
75
52
Grok
77

Key Details

Category
Base Editing Gene Therapy
Genomic Infectious Disease Diagnostics
Tier
Growth
Leader
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Beam Therapeutics
Base Editing Gene Therapy

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.